AbbVie is seeing high success rate, including in difficult patient populations, using only two drugs and not including an NS5B inhibitor!

LET THE PRICE COMPETITION BEGIN!!!!

http://www.prnewswire.com/news-releases/abbvies-investigational-pan-genotypic-regimen-of-abt-493-and-abt-530-shows-high-svr-rates-in-genotype-1-hepatitis-c-patients-who-failed-previous-therapy-with-direct-acting-antivirals-300252074.html

and

http://www.prnewswire.com/news-releases/abbvie-presents-new-phase-2-data-for-investigational-once-daily-ribavirin-free-pan-genotypic-regimen-of-abt-493-and-abt-530-for-hepatitis-c-genotypes-1-6-300252344.html